Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P < .001). An exploratory analysis of phase 3 trial data evaluated the influence of rearranged during transfection ( RET ) and RAS (HRAS, KRAS, and NRAS) mutations on cabozantinib clinical activity. METHODS Patients (n = 330) were randomized to cabozantinib (140 mg/day) or a...